Atossa Genetics (NASDAQ:ATOS) Stock Price Passes Below 200 Day Moving Average - Time to Sell?

Key Points

• Atossa Genetics shares have fallen below their 200-day moving average, closing at $0.76, which may signal a potential sell opportunity for investors.
• Research firms are offering varied ratings and price targets for Atossa Genetics, with Craig Hallum issuing a "strong-buy" rating at a target of $4.00 and Ascendiant Capital increasing their target to $7.50.
• Institutional investors have been active in the stock, with firms like Two Sigma Advisers and Wells Fargo significantly increasing their stakes in the company during the fourth quarter.

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.76. Atossa Genetics shares last traded at $0.76, with a volume of 859,004 shares changing hands.

Analysts Set New Price Targets

Several research firms have commented on ATOS. Craig Hallum raised shares of Atossa Genetics to a "strong-buy" rating and set a $4.00 price objective for the company in a report on Thursday, June 5th. Ascendiant Capital Markets increased their price objective on shares of Atossa Genetics from $7.25 to $7.50 and gave the company a "buy" rating in a report on Friday, June 6th.

Atossa Genetics Stock Performance

The stock's fifty day moving average is $0.85 and its 200 day moving average is $0.80. The stock has a market cap of $98.60 million, a P/E ratio of -3.63 and a beta of 0.92.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Equities research analysts predict that Atossa Genetics Inc. will post -0.22 EPS for the current year.

Institutional Trading of Atossa Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATOS. Millennium Management LLC purchased a new stake in Atossa Genetics in the 4th quarter worth about $28,000. Two Sigma Advisers LP raised its position in Atossa Genetics by 214.1% in the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after purchasing an additional 28,900 shares during the period. Wells Fargo & Company MN raised its position in Atossa Genetics by 30.7% in the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after purchasing an additional 16,853 shares during the period. XTX Topco Ltd raised its position in Atossa Genetics by 59.6% in the 4th quarter. XTX Topco Ltd now owns 79,176 shares of the company's stock worth $75,000 after purchasing an additional 29,560 shares during the period. Finally, Bank of America Corp DE raised its position in Atossa Genetics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company's stock worth $105,000 after purchasing an additional 37,809 shares during the period. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.